Guillain‑Barré syndrome (muscle weakness) - Causes, Treatment & When to See a Doctor

```html

What is Guillain‑Barré syndrome (muscle weakness)?

Guillain‑Barré syndrome (GBS) is an acute, immune‑mediated disorder in which the body’s immune system mistakenly attacks the peripheral nerves—those that connect the brain and spinal cord to the muscles and sensory organs. The attack damages the myelin sheath (the protective covering) and sometimes the nerve fibers themselves, leading to rapid onset of muscle weakness, tingling, and loss of reflexes.

Most people experience the first signs within a few weeks after a preceding infection, vaccination, or other immune‑stimulating event. The weakness typically begins in the legs and ascends upward, but can also start in the arms or face. Although GBS can be life‑threatening when respiratory muscles or the autonomic nervous system become involved, the majority of patients recover fully or with only mild residual deficits when treated promptly.

Sources: Mayo Clinic, 2023; National Institute of Neurological Disorders and Stroke (NINDS), 2022.

Common Causes

GBS is not caused by a single factor; rather, it follows an immune trigger. The most frequently identified precipitating events include:

• Respiratory infections – especially Campylobacter jejuni (a common cause of food‑borne diarrhea).
• Gastrointestinal infections – such as Salmonella, Shigella, or E. coli.
• Viral infections – influenza, Epstein‑Barr virus, cytomegalovirus, and Zika virus.
• Vaccinations – rare cases have been reported after influenza, COVID‑19, and other vaccines (the overall risk is extremely low).
• Surgery – postoperative immune activation can precede GBS.
• Autoimmune diseases – systemic lupus erythematosus or rheumatoid arthritis may increase susceptibility.
• HIV infection – can trigger GBS during seroconversion.
• Hematologic disorders – such as lymphoma or leukemia, which alter immune regulation.
• Paraneoplastic syndromes – nerve damage caused by an immune response to cancer.
• Other rare triggers – including exposure to certain toxins or medications (e.g., certain anti‑parasitics).

Associated Symptoms

While muscle weakness is the hallmark, many patients experience additional neurologic and systemic signs:

• Tingling or “pins‑and‑needles” sensation (paraesthesia) that usually starts in the feet and hands.
• Loss of deep tendon reflexes (e.g., absent knee‑jerk).
• Pain – often described as aching or cramping in the back, thighs, or calves.
• Facial weakness – leading to difficulty closing eyes or smiling.
• Difficulty swallowing or speaking (bulbar involvement).
• Respiratory muscle weakness – shortness of breath, especially when lying flat.
• Autonomic dysfunction – fluctuating blood pressure, heart‑rate irregularities, abnormal sweating, or bladder/bowel problems.
• Fatigue – profound tiredness that does not improve with rest.

Symptoms usually progress over a period of 3‑4 days to 4 weeks, reach a "plateau" phase, and then gradually improve over weeks to months.

When to See a Doctor

GBS can advance quickly, and early medical attention dramatically improves outcomes. Seek care immediately if you notice:

• Sudden, rapidly spreading muscle weakness in the legs or arms.
• Difficulty walking, climbing stairs, or rising from a chair.
• Facial drooping, trouble speaking, or swallowing.
• Unexplained tingling or numbness that spreads upward.
• Breathing difficulty, shortness of breath, or chest tightness.
• Severe pain that does not respond to over‑the‑counter analgesics.

Even if symptoms are mild, a prompt neurological evaluation is essential because early treatment (within 2 weeks of symptom onset) reduces the risk of severe complications.

Diagnosis

Diagnosing GBS involves a combination of clinical assessment, laboratory tests, and electrophysiological studies.

Clinical Evaluation

• Detailed medical history focusing on recent infections, vaccinations, or surgeries.
• Neurological exam to assess muscle strength, reflexes, sensation, and cranial‑nerve function.

Electrodiagnostic Tests

• Electromyography (EMG) and Nerve‑Conduction Studies (NCS) – show slowed conduction velocities or blockages consistent with demyelination.

Laboratory Tests

• Cerebrospinal fluid (CSF) analysis – typically reveals elevated protein with normal white‑cell count (“albumin‑cytologic dissociation”).
• Blood tests to rule out other causes (e.g., diabetes, Lyme disease) and to look for antecedent infections (e.g., Campylobacter antibodies).

Imaging

• MRI of the spine may be done to exclude spinal cord compression or transverse myelitis.

Diagnostic Criteria

Most clinicians use the Brighton Collaboration criteria, which combine clinical features, CSF findings, and electrophysiology to assign a level of diagnostic certainty.

Treatment Options

Management of GBS is aimed at halting the immune attack, supporting vital functions, and facilitating rehabilitation.

Immunotherapy

• Intravenous Immunoglobulin (IVIG) – a standard first‑line therapy (0.4 g/kg/day for 5 days). It neutralizes harmful antibodies and has been shown to speed recovery.
• Plasma Exchange (Plasmapheresis) – removes circulating antibodies; usually 4‑6 exchanges over 1‑2 weeks. Equivalent efficacy to IVIG; choice depends on availability and patient tolerance.

Supportive Care

• Monitoring of respiratory function – frequent measurement of vital capacity and negative inspiratory force; early intubation if needed.
• Cardiovascular & autonomic monitoring – continuous ECG, blood‑pressure checks, and treatment of arrhythmias or labile hypertension.
• Pain management – neuropathic pain often responds to gabapentin, pregabalin, or low‑dose tricyclic antidepressants.
• Physical and occupational therapy – early passive range‑of‑motion exercises prevent contractures; progressive strengthening as strength returns.
• Bladder and bowel care – catheterization or bowel programs as required.

Home / Self‑Care Measures (post‑hospital)

• Gradual, therapist‑guided activity progression; avoid over‑exertion.
• Use of assistive devices (walker, ankle‑foot orthoses) until balance improves.
• Skin‑care to prevent pressure ulcers.
• Nutrition optimization – high‑protein diet to aid nerve regeneration.
• Psychological support – coping with fatigue and anxiety is common.

Prevention Tips

Because GBS is triggered by immune activation, absolute prevention is impossible, but risk can be minimized:

• Practice good hand hygiene and food safety to reduce gastrointestinal infections (especially Campylobacter).
• Stay up‑to‑date with vaccinations; the protective benefits far outweigh the very small GBS risk.
• Promptly treat respiratory or gastrointestinal infections with appropriate antibiotics when indicated.
• Maintain a healthy immune system – balanced diet, regular exercise, adequate sleep, and stress management.
• If you have a history of GBS, discuss future vaccinations with your physician; some guidelines recommend special precautions.

Emergency Warning Signs

Prognosis & Outlook

With early treatment, 70‑80 % of patients recover the ability to walk independently within 6 months. However, 10‑20 % may experience persistent weakness, fatigue, or neuropathic pain for years. A small minority develop chronic inflammatory demyelinating polyneuropathy (CIDP), a related condition that requires long‑term immunotherapy.

Regular follow‑up with a neurologist, physiotherapist, and primary‑care provider is essential to monitor recovery, adjust therapy, and manage complications.

References:
1. Mayo Clinic. Guillain‑Barré syndrome. 2023. https://www.mayoclinic.org.
2. National Institute of Neurological Disorders and Stroke. Guillain‑Barré Syndrome Fact Sheet. 2022. https://www.ninds.nih.gov.
3. CDC. Guillain‑Barré Syndrome and Vaccines. 2021. https://www.cdc.gov.
4. Cleveland Clinic. Guillain‑Barré Syndrome Treatment Options. 2024. https://my.clevelandclinic.org.
5. van Doorn PA, et al. Guillain‑Barré syndrome. The Lancet. 2023;401:1153‑1166.

```